LY2951742 + Celecoxib
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis, Knee
Conditions
Osteoarthritis, Knee
Trial Timeline
Jul 1, 2014 → Jun 1, 2015
NCT ID
NCT02192190About LY2951742 + Celecoxib
LY2951742 + Celecoxib is a phase 2 stage product being developed by Eli Lilly for Osteoarthritis, Knee. The current trial status is terminated. This product is registered under clinical trial identifier NCT02192190. Target conditions include Osteoarthritis, Knee.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02192190 | Phase 2 | Terminated |
Competing Products
20 competing products in Osteoarthritis, Knee